S&P 500   4,666.63 (+1.57%)
DOW   35,221.15 (+0.92%)
QQQ   400.23 (+2.31%)
AAPL   160.59 (+2.41%)
MSFT   337.95 (+2.51%)
FB   338.81 (+1.71%)
GOOGL   2,913.94 (+2.47%)
AMZN   3,588.40 (+2.39%)
TSLA   1,140.49 (+5.41%)
NVDA   329.61 (+4.63%)
BABA   131.95 (-1.05%)
NIO   40.28 (+0.73%)
CGC   11.13 (-4.79%)
AMD   159.99 (+3.35%)
GE   98.89 (+1.07%)
MU   85.18 (+2.11%)
T   24.02 (-0.83%)
F   19.86 (+0.56%)
DIS   147.61 (-0.34%)
ACB   6.50 (-4.27%)
AMC   37.16 (-1.25%)
PFE   53.84 (-0.30%)
BA   198.88 (-0.17%)
S&P 500   4,666.63 (+1.57%)
DOW   35,221.15 (+0.92%)
QQQ   400.23 (+2.31%)
AAPL   160.59 (+2.41%)
MSFT   337.95 (+2.51%)
FB   338.81 (+1.71%)
GOOGL   2,913.94 (+2.47%)
AMZN   3,588.40 (+2.39%)
TSLA   1,140.49 (+5.41%)
NVDA   329.61 (+4.63%)
BABA   131.95 (-1.05%)
NIO   40.28 (+0.73%)
CGC   11.13 (-4.79%)
AMD   159.99 (+3.35%)
GE   98.89 (+1.07%)
MU   85.18 (+2.11%)
T   24.02 (-0.83%)
F   19.86 (+0.56%)
DIS   147.61 (-0.34%)
ACB   6.50 (-4.27%)
AMC   37.16 (-1.25%)
PFE   53.84 (-0.30%)
BA   198.88 (-0.17%)
S&P 500   4,666.63 (+1.57%)
DOW   35,221.15 (+0.92%)
QQQ   400.23 (+2.31%)
AAPL   160.59 (+2.41%)
MSFT   337.95 (+2.51%)
FB   338.81 (+1.71%)
GOOGL   2,913.94 (+2.47%)
AMZN   3,588.40 (+2.39%)
TSLA   1,140.49 (+5.41%)
NVDA   329.61 (+4.63%)
BABA   131.95 (-1.05%)
NIO   40.28 (+0.73%)
CGC   11.13 (-4.79%)
AMD   159.99 (+3.35%)
GE   98.89 (+1.07%)
MU   85.18 (+2.11%)
T   24.02 (-0.83%)
F   19.86 (+0.56%)
DIS   147.61 (-0.34%)
ACB   6.50 (-4.27%)
AMC   37.16 (-1.25%)
PFE   53.84 (-0.30%)
BA   198.88 (-0.17%)
S&P 500   4,666.63 (+1.57%)
DOW   35,221.15 (+0.92%)
QQQ   400.23 (+2.31%)
AAPL   160.59 (+2.41%)
MSFT   337.95 (+2.51%)
FB   338.81 (+1.71%)
GOOGL   2,913.94 (+2.47%)
AMZN   3,588.40 (+2.39%)
TSLA   1,140.49 (+5.41%)
NVDA   329.61 (+4.63%)
BABA   131.95 (-1.05%)
NIO   40.28 (+0.73%)
CGC   11.13 (-4.79%)
AMD   159.99 (+3.35%)
GE   98.89 (+1.07%)
MU   85.18 (+2.11%)
T   24.02 (-0.83%)
F   19.86 (+0.56%)
DIS   147.61 (-0.34%)
ACB   6.50 (-4.27%)
AMC   37.16 (-1.25%)
PFE   53.84 (-0.30%)
BA   198.88 (-0.17%)

Sema4 (NASDAQ:SMFR) Downgraded by Zacks Investment Research

Last updated on Thursday, November 25, 2021 | 2021 MarketBeat

Sema4 (NASDAQ:SMFR) was downgraded by Zacks Investment Research from a "hold" rating to a "sell" rating in a research report issued on Thursday, Zacks.com reports.

According to Zacks, "Sema4 Holdings Corp is a patient-centered health intelligence company. It is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. Sema4 Holdings Corp, formerly known as CM Life Sciences, is based in STAMFORD, Conn. "

Several other research firms have also recently commented on SMFR. Jefferies Financial Group started coverage on Sema4 in a report on Friday, September 24th. They issued a "buy" rating and a $13.00 price target for the company. Cowen started coverage on Sema4 in a report on Thursday, September 30th. They set an "outperform" rating and a $13.00 target price for the company. BTIG Research started coverage on Sema4 in a report on Friday, October 8th. They set a "buy" rating and a $12.00 target price for the company. Finally, The Goldman Sachs Group started coverage on Sema4 in a report on Friday, November 19th. They set a "buy" rating and a $12.00 target price for the company. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $12.50.

SMFR opened at $6.76 on Thursday. The company has a 50-day simple moving average of $7.91. Sema4 has a 12 month low of $6.30 and a 12 month high of $27.18.

Sema4 (NASDAQ:SMFR) last posted its quarterly earnings results on Monday, November 15th. The company reported $0.15 EPS for the quarter, beating the consensus estimate of ($0.19) by $0.34. The business had revenue of $43.18 million during the quarter, compared to analysts' expectations of $42.00 million. As a group, equities research analysts forecast that Sema4 will post -0.55 earnings per share for the current fiscal year.

In related news, CFO Isaac Ro sold 40,848 shares of the business's stock in a transaction that occurred on Monday, October 25th. The stock was sold at an average price of $7.54, for a total transaction of $307,993.92. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO James Coffin sold 5,752 shares of the company's stock in a transaction that occurred on Monday, October 25th. The shares were sold at an average price of $7.54, for a total value of $43,370.08. The disclosure for this sale can be found here. Insiders have sold a total of 105,438 shares of company stock valued at $815,461 in the last quarter.

Institutional investors and hedge funds have recently made changes to their positions in the business. Royal Bank of Canada acquired a new position in shares of Sema4 in the 3rd quarter valued at approximately $36,000. Citigroup Inc. acquired a new position in shares of Sema4 in the 3rd quarter valued at approximately $79,000. Victory Capital Management Inc. acquired a new position in shares of Sema4 in the 3rd quarter valued at approximately $88,000. Clearwater Capital Advisors LLC bought a new stake in shares of Sema4 in the 3rd quarter valued at approximately $93,000. Finally, Tudor Investment Corp Et Al bought a new stake in shares of Sema4 in the 3rd quarter valued at approximately $106,000. 74.08% of the stock is currently owned by institutional investors.

About Sema4

Sema4 Holdings Corp is a patient-centered health intelligence company. It is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. Sema4 Holdings Corp, formerly known as CM Life Sciences, is based in STAMFORD, Conn.

Featured Story: What is the LIBOR?

Get a free copy of the Zacks research report on Sema4 (SMFR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in Sema4 right now?

Before you consider Sema4, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sema4 wasn't on the list.

While Sema4 currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

 


Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.